BookYasuhiko Tomino., editor
Part I. Pathogenesis -- Chapter 1. Is IgA nephropathy the same disease/a homogenous disease? -- Chapter 2. Genetic variations of IgA nephropathy -- Chapter 3. Is IgA nephropathy a familial or sporadic disease? -- Chapter 4. Heterogeneity of GdIgA1 -- Chapter 5. Differences of histological classification between the Japanese guideline and the Oxford classification -- Chapter 6. Podocyte injury and the role of megalin -- Chapter 7. Complement activation -- Part II. Treatment -- Chapter 8. How different are the current understandings of treatments for IgA nephropathy? -- Chapter 9. Differences in etiology and treatment in China -- Chapter 10. Differences in etiology and treatment in Korea -- Chapter 11. Differences in etiology and treatment in Japan -- Chapter 12. The VALIGA study: Differences in treatment approaches within the EU -- Chapter 13. Differences in etiology and treatment in Scandinavian countries -- Chapter14 The Implication of the KDIGO Clinical Practice Guidelines on management of IgA Nephropathy -- Chapter15 Japanese Clinical Practice Guidelines for IgA Nephropathy: Difference from KDIGO Guidelines -- Chapter16 Limitations of RAS blockade in IgA nephropathy -- Chapter17 What is the goal for proteinuria in IgA nephropathy? -- Chapter 18. Rationale of tonsillectomy and steroid pulse therapy (TSP): Is it race dependent? -- Chapter 19. Is tonsillectomy a possible treatment for IgA nephropathy from RCT? -- Chapter 20. Is tonsillectomy a possible treatment for IgA nephrology from a retrospective analysis?.